论文部分内容阅读
特发性血小板减少性紫癜(ITP)是临床常见的出血疾病。重组人血小板生成素(rhTPO)是特异性的血小板刺激因子,可调节巨核细胞的增殖分化与成熟,有效增加外周血血小板计数,可能成为治疗难治性ITP的一种新选择。本研究观察了23例难治ITP患者对rhTPO的治疗效果,现报告如下。1资料与方法1.1一般资料:选取2005年1月至2010年1月在中国医科大学附属第一医院血液科住院的难治性ITP患者23例,其中男性9例,女性14例,年龄18～69岁,中位年龄37岁。
Idiopathic thrombocytopenic purpura (ITP) is a common clinical bleeding disease. Recombinant human thrombopoietin (rhTPO) is a specific platelet-stimulating factor that regulates the proliferation, differentiation and maturation of megakaryocytes and effectively increases the peripheral blood platelet count, which may be a new option for the treatment of refractory ITP. This study observed the treatment of 23 patients with intractable ITP rhTPO treatment, are as follows. 1 Materials and Methods 1.1 General Information: Twenty-three patients with refractory ITP admitted to Department of Hematology, The First Affiliated Hospital of China Medical University from January 2005 to January 2010 were selected, including 9 males and 14 females, aged 18 ~ 69 years old, the median age 37 years old.